Deer Park, Illinois – July 14, 2026 – Leica Biosystems, a Danaher Company (the “Company”) and a global leader in anatomic pathology solutions that advance precision cancer diagnosis, today announced that Leica Biosystems has entered into a definitive agreement to acquire privately held StatLab Medical Products (“StatLab”), a global developer and manufacturer of anatomic pathology products, from Linden Capital Partners and Audax. private equity. After closure, StatLab will become part of Leica Biosystems.
For more than 50 years, StatLab has been a trusted partner for anatomic pathology laboratories, offering a broad portfolio of high-quality products across preanalytical and analytical histology workflows. From specimen collection and tissue processing to slide preparation and staining, StatLab’s solutions help laboratories improve efficiency, standardization, and diagnostic quality. Built on a strong reputation for quality, innovation and customer partnerships, StatLab shares Leica Biosystems’ commitment to advancing cancer diagnostics and improving patient outcomes around the world.
“We are excited about the opportunity to combine StatLab’s trusted portfolio with Leica Biosystems’ global leadership in pathology, computational pathology, and AI-enabled diagnostics. By helping laboratories achieve the consistency, standardization, and quality needed to deploy AI-enabled cancer diagnostics at scale, we can work together to solve some of healthcare’s toughest problems,” said Gustavo Perez, Danaher Diagnostics Business Group Executive and Leica President. Fernandes said. biosystem. “We look forward to welcoming this talented team to Leica Biosystems. Every step we take to accelerate critical cancer diagnosis will help patients get on the path to treatment faster.”
The transaction is expected to close by the end of 2026 and is subject to customary conditions, including receipt of applicable regulatory approvals. Financial terms of the acquisition were not disclosed.
About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in anatomy and digital pathology solutions. The company’s comprehensive portfolio helps pathology laboratories and clinicians improve cancer diagnosis. The company’s mission to “Advance Cancer Diagnosis, Improve Lives” is central to its corporate culture. Leica Biosystems is proud to be a subsidiary of Danaher Corporation.
About Danaher
Danaher is a world-leading life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health. Our business works closely with our customers to solve many of the most important health challenges affecting patients around the world. Danaher’s advanced science and technology and proven innovation capabilities enable faster, more accurate diagnosis and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing treatments. With a focus on scientific excellence, innovation and continuous improvement, Danaher’s approximately 60,000 employees worldwide consistently improve the quality of life for billions of people today and lay the foundation for a healthier, more sustainable tomorrow. For more information, please visit www.danaher.com.
Cautionary note regarding forward-looking statements
Other than statements of historical fact contained in this communication, all statements made by the Company that refer to activities, events, or developments that will or may occur in the future are forward-looking statements, including, among other things, statements regarding the expected timing, completion, and effects or benefits of the acquisition of StatLab (the “Transaction”). These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control, and which could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: (i) uncertainty regarding the timing of transactions; (ii) the risk that the transaction may not be completed on a timely basis or at all; (iii) failure to satisfy any of the conditions to consummation; (iv) the possibility that some or all of the various conditions to the completion of the transaction may not be satisfied or waived, including the failure to receive necessary regulatory approvals (or conditions, limitations or restrictions imposed on such approvals) from applicable governmental agencies; (v) the occurrence of events, changes or other circumstances that may cause termination of the Acquisition Agreement; (vi) the impact of the announcement or suspension of the Transaction on our ability to hire and retain key personnel, our ability to maintain relationships with customers and suppliers, and our results of operations and business generally; (vii) risks associated with diverting management’s attention from ongoing business operations; (viii) the risk that the benefits of the Transaction will not be realized as expected or when; (ix) legislative, regulatory, and economic development; and (x) other factors discussed in the “Risk Factors” section of Danaher’s most recent periodic reports filed with the SEC, including the Company’s 2025 Annual Report on Form 10-K and 2026 First Quarter Quarterly Report on Form 10-Q. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we cannot be certain that our expectations will prove to be correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and even if subsequently published, including on our website. We undertake no obligation to update, revise or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
